Brazil interested in investing $4.5 Billion in Ukraine, including pharma

19 November 2012

Brazil has submitted to Ukrainian authorities $4.5 billion worth of investment proposals. "We want to build the mini-tractors production plant in Ukraine as well as purchase shipbuilding and pharmaceutical manufacturing technology," said Jose Barouki, director of trade and investment company Daruvar SA during the Ukrainian investment roadshow in Sao Paulo, Brazil.

According to the advisor to the President Brazilian Development Bank D Rodriguez, Ukraine could become a very interesting platform for Brazilian investors, especially given the strategic location of Ukraine. The Bank will consider investing into National Projects of Ukraine.

Already has human insulin accord

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >